Authors
Latest:
Evolving Understanding and Treatment of Smoldering Multiple Sclerosis: Antonio Scalfari, MD, PhDThe consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]
Latest:
A National Registry Analysis on Minimally Invasive Surgery for Intracerebral Hemorrhage: Santosh Murthy, MD, MPHThe associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Latest:
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhDThe senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
Latest:
Stroke Intervention: A New Application of Interventional NeuroradiologyNew training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.
Latest:
Swallow This: Treating Dysphagia with Speech PathologyStephanie Richardson, MS, CCC-SLP, an outpatient lead speech-language pathologist at Brooks Rehabilitation, discussed the unique aspects of speech therapy and the pivotal role it plays in helping patients with swallowing and other related functions.
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
Latest:
The Outlook for Apitegromab and Its Phase 3 Trial: Yung Chyung, MDThe chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.
Latest:
Early Insights on 3 Patients With DMD From Trial Assessing Gene Therapy RGX-202: Aravindhan Veerapandiyan, MDThe pediatric neuromuscular neurologist at Arkansas Children's Hospital and associate professor of pediatrics at the University of Arkansas for Medical Sciences talked about findings from a phase 1/2 study on dosing 3 pediatric patients with Duchenne muscular dystrophy with REGENXBIO’s RGX-202. [WATCH TIME: 4 minutes]
Latest:
Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhDThe neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
Latest:
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MDAs the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
Latest:
Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer DiseaseThe professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.
Latest:
Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep ApneaRecent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
Latest:
Jan Hillert, MD, PhD: Stem Cell Transplants in MSThe professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.
Latest:
Danny Eckert, PhD: Pharmacotherapies Reducing OSA SeverityProof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.
Latest:
The Evolutionary Arch of Stereoelectroencephalography in the United StatesSEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.
Latest:
Alzheimer Disease: Separating Fact from FictionIn honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Latest:
Groundbreaking Epilepsy Research Studies on the Horizon in 2023: Anup Patel, MDThe pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]
Latest:
Jeffrey Buchhalter, MD: Disclosing SUDEP Risk to Patients With EpilepsyThe pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.
Latest:
2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MDThe codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]
Latest:
Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic ConditionsThe professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.
Latest:
Amy B. Sullivan, PsyD: Screening MS Patients for ComorbiditiesThe director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.
Latest:
Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DScThe professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Latest:
Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MScThe associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Latest:
CMSC Live: 2024 Annual Meeting Day 1Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Latest:
Lutz Frolich, MD, PhD: Learning from Negative TrialsLutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
